Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) just unveiled an update.
MindBio Therapeutics has listed its common shares for trading on the OTCQB Market in the United States, a move that broadens its access to U.S. investors and aligns with a roadshow promoting its AI-powered drug and alcohol intoxication detection technology. The company recently launched its Booze AI app, which uses an AI model trained on more than 50 million data points to assess alcohol intoxication and estimate blood alcohol concentration from voice alone, and is now developing enterprise-grade and platform-level solutions targeting workplace safety, call centres, mental health, and law enforcement, potentially strengthening its commercial prospects and competitive positioning in AI-driven health monitoring.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a Vancouver-based biotechnology company focused on drug and alcohol research and the development of AI- and machine-learning-driven health prediction technologies. Leveraging speech analytics, it has created voice-based models to detect and predict drug and alcohol intoxication, and is building an enterprise platform aimed at applications in workplaces, law enforcement, mental health, and telehealth.
Average Trading Volume: 3,805
Technical Sentiment Signal: Hold
Current Market Cap: C$2.02M
For detailed information about MBIO stock, go to TipRanks’ Stock Analysis page.